AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Written by Petra Hegmann on 8th July 2021. Posted in Client News.

• Previous
• Next